Literature DB >> 7603984

Growth suppression by p16ink4 requires functional retinoblastoma protein.

R H Medema1, R E Herrera, F Lam, R A Weinberg.   

Abstract

p16ink4 has been implicated as a tumor suppressor that is lost from a variety of human tumors and human cell lines. p16ink4 specifically binds and inhibits the cyclin-dependent kinases 4 and 6. In vitro, these kinases can phosphorylate the product of the retinoblastoma tumor suppressor gene. Thus, p16ink4 could exert its function as tumor suppressor through inhibition of phosphorylation and functional inactivation of the retinoblastoma protein. Here we show that overexpression of p16ink4 in certain cell types will lead to an arrest in the G1 phase of the cell cycle. In addition, we show that p16ink4 can only suppress the growth of human cells that contain functional pRB. Moreover, we have compared the effect of p16ink4 expression on embryo fibroblasts from wild-type and RB homozygous mutant mice. Wild-type embryo fibroblasts are inhibited by p16ink4, whereas the RB nullizygous fibroblasts are not. These data not only show that the presence of pRB is crucial for growth suppression by p16ink4 but also indicate that the pRB is the critical target acted upon by cyclin D-dependent kinases in the G1 phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603984      PMCID: PMC41503          DOI: 10.1073/pnas.92.14.6289

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.

Authors:  Y Gu; C W Turck; D O Morgan
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

2.  Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.

Authors:  L Zhu; S van den Heuvel; K Helin; A Fattaey; M Ewen; D Livingston; N Dyson; E Harlow
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

3.  Function of a human cyclin gene as an oncogene.

Authors:  P W Hinds; S F Dowdy; E N Eaton; A Arnold; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

4.  Inhibition of ras-induced proliferation and cellular transformation by p16INK4.

Authors:  M Serrano; E Gómez-Lahoz; R A DePinho; D Beach; D Bar-Sagi
Journal:  Science       Date:  1995-01-13       Impact factor: 47.728

5.  Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.

Authors:  Y Xiong; H Zhang; D Beach
Journal:  Genes Dev       Date:  1993-08       Impact factor: 11.361

6.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

7.  Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.

Authors:  Z A Khatib; H Matsushime; M Valentine; D N Shapiro; C J Sherr; A T Look
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

9.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

10.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  112 in total

1.  Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization.

Authors:  J Sage; G J Mulligan; L D Attardi; A Miller; S Chen; B Williams; E Theodorou; T Jacks
Journal:  Genes Dev       Date:  2000-12-01       Impact factor: 11.361

2.  Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro.

Authors:  P Pantazis; D Chatterjee; Z Han; J Wyche
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

3.  Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1).

Authors:  P F Dijkers; R H Medema; C Pals; L Banerji; N S Thomas; E W Lam; B M Burgering; J A Raaijmakers; J W Lammers; L Koenderman; P J Coffer
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  Transcriptomic classification of antitumor agents: application to the analysis of the antitumoral effect of SR31747A.

Authors:  Jean-Bernard Ferrini; Omar Jbilo; Annick Peleraux; Therese Combes; Hubert Vidal; Sylvaine Galiegue; Pierre Casellas
Journal:  Gene Expr       Date:  2003

5.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

6.  Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells.

Authors:  Tiziana Parisi; Andreas R Beck; Nathalie Rougier; Tom McNeil; Linda Lucian; Zena Werb; Bruno Amati
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

7.  Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.

Authors:  V G Gorgoulis; E N Koutroumbi; A Kotsinas; P Zacharatos; C Markopoulos; L Giannikos; V Kyriakou; Z Voulgaris; I Gogas; C Kittas
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

8.  Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression.

Authors:  H Jiang; H S Chou; L Zhu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.

Authors:  G Busatto; Y H Shiao; A R Parenti; R Baffa; A Ruol; M Plebani; M Rugge
Journal:  Mol Pathol       Date:  1998-04

10.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.